Amyris, Inc. announced that it will acquire Oobli Inc., a Davis, California-based developer of fermentation-derived sweet proteins, in a move that would add a sugar-reduction ingredient platform to Amyris's biomanufacturing business. Amyris, based in Emeryville, California, is a vertically integrated biomanufacturing company; Oobli focuses on sweet proteins made through fermentation for food and beverage customers seeking to reduce sugar while retaining sweetness.
The companies present the transaction as a combination of complementary capabilities. Amyris would contribute strain engineering, manufacturing scale and commercial reach, while Oobli would bring expertise in producing sweet proteins through fermentation. Amyris said the deal follows an expansion of manufacturing capacity earlier this year at its fermentation facility in Barra Bonita, Brazil, and would support its broader push into protein- and peptide-based solutions across end markets.
Platform and product portfolio
Oobli's sweet-protein portfolio would be the first business to benefit from the combined platform. Oobli has spent the past decade developing a fermentation process for sweet proteins that occur naturally in rare fruits and berries found near the equator. The portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit Sweet Proteins, known scientifically as brazzein, monellin and thaumatin, respectively.
According to the companies, these proteins are hundreds to thousands of times sweeter than sugar, bind directly to sweet-taste receptors and are metabolized by the body as protein. Oobli says the ingredients can deliver sweetness without gut disruption or blood-sugar spikes; those are company statements, and the announcement does not provide independent verification. The portfolio has FDA GRAS status as an ingredient and is FEMA GRAS-affirmed for use as a natural flavor, according to the companies.
The companies see applications across sports and nutrition products, dairy, beverages, chocolate, bakery and confectionery. They point to growing consumer interest in metabolic health and sugar reduction as demand drivers for ingredients that can lower sugar content while maintaining taste.
Executive views and next steps
Amyris CEO Kathy Fortmann said Oobli offers a commercial and technology platform that complements Amyris's own. She said Oobli is positioned to change how sweetness reaches the market, and that Amyris hopes to use its scale and resources to accelerate that effort. Fortmann also said combining Oobli's protein expertise with Amyris's strain engineering, manufacturing and commercial capabilities could broaden opportunities in food and beverage, personal care, flavors and fragrances, agriculture and other markets.
Oobli CEO Ali Wing said the company has long sought a way to provide the sweet taste consumers want without the health and environmental trade-offs associated with conventional sweetness solutions. She said joining Amyris would give Oobli the scale and resources to pursue its goal of making sweet proteins a standard option for sweetness. Fortmann added that biomanufactured solutions tend to succeed when they match consumer demand and market needs, and said Oobli's platform addresses sweetness, sugar reduction and clean-label goals together.
The acquisition is expected to close in the coming weeks. Until then, the transaction remains subject to completion. Amyris said all existing customer commitments and brand partnerships will continue without interruption as Oobli's sweet-protein portfolio expands within the combined company.
